Surface Design for Powder on Dry Process

Particulate Interactions in Dry Powder Formulations for Inhalation Particulate Interactions in Dry Powder Formulations for Inhalation

Assessing dry powder inhalers

To enable what would otherwise be impractical, invasive and potentially dangerous testing, and to remove the huge variation and costs associated with human subjects, it is common practice to test inhalation devices and formulations using in vitro test apparatus. Industry standard test conditions and relevant parameters have been devised and published by the regulatory authorities and within the...

Dry powder inhaler formulation.

A drug product combines pharmacologic activity with pharmaceutical properties. Desirable performance characteristics are physical and chemical stability, ease of processing, accurate and reproducible delivery to the target organ, and availability at the site of action. For the dry powder inhaler (DPI), these goals can be met with a suitable powder formulation, an efficient metering system, and ...

Dry powder inhalers for pulmonary drug delivery.

The pulmonary route is an interesting route for drug administration, both for effective local therapy (asthma, chronic obstructive pulmonary disease or cystic fibrosis) and for the systemic administration of drugs (e.g., peptides and proteins). Well-designed dry powder inhalers are highly efficient systems for pulmonary drug delivery. However, they are also complicated systems, the the performa...

Vibration Technology for Active Dry-Powder Inhalers

Timothy M. Crowder, PhD, is chief technology officer at Oriel Therapeutics, Inc., PO Box 14087, Research Triangle Park, NC 27709, tel. 919.313.1290 ext. 11, fax 919.313.1295, [email protected]. ctive dry-powder inhalers (DPIs) for pulmonary drug delivery have been under development for at least 10 years, but to date no such device has been approved by FDA. Like propellant-driven me...